Preclinical studies and early clinical trials indicate sensitivity to inhibitors of PI3K in several cancers including breast, ovarian, endometrial, lung and multiple myeloma [18, 23–29]. The gene discussed is PIK3CA; the disease is plasma cell myeloma.